Unity Biotechnology (NASDAQ:UBX – Free Report) had its price objective trimmed by Chardan Capital from $6.00 to $4.00 in a report issued on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.
Separately, HC Wainwright lowered their price target on shares of Unity Biotechnology from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Monday.
View Our Latest Report on Unity Biotechnology
Unity Biotechnology Stock Down 2.7 %
Hedge Funds Weigh In On Unity Biotechnology
A hedge fund recently raised its stake in Unity Biotechnology stock. Geode Capital Management LLC increased its stake in shares of Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) by 9.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 163,242 shares of the company’s stock after acquiring an additional 14,199 shares during the quarter. Geode Capital Management LLC owned about 0.97% of Unity Biotechnology worth $240,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 29.49% of the company’s stock.
About Unity Biotechnology
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
Read More
- Five stocks we like better than Unity Biotechnology
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- Growth Stocks: What They Are, What They Are Not
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Are Penny Stocks a Good Fit for Your Portfolio?
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.